{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-026017","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2022-12-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.432308+00:00","generated_at":"2026-06-21T09:29:02.760483+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Syndax appoints Steve Sabus as CCO; base $495K, option for 220K shares","bullets":["Steve Sabus joins as Chief Commercial Officer effective December 5, 2022.","Annual base salary of $495,000 with target bonus of 40% and option grant for 220,000 shares.","Sabus previously CCO at Turning Point Therapeutics and 15-year Astellas veteran.","Role focuses on commercial strategy for potential 2024 launches of revumenib and axatilimab.","Severance includes 9-month base salary on termination w/o cause or good reason; 12-month + full vesting on change in control."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-026017","json":"https://secwatch.observer/filing/0000950170-22-026017.json","markdown":"https://secwatch.observer/filing/0000950170-22-026017.md","text":"https://secwatch.observer/filing/0000950170-22-026017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000095017022026017/0000950170-22-026017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000095017022026017/sndx-20221201.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T09:29:02.760483+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ad070fa996","claim":"Steve Sabus was appointed as Chief Commercial Officer at Syndax Pharmaceuticals Inc.","evidence_excerpt":"On December 2, 2022, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Steve Sabus will join the Company as Chief Commercial Officer, effective December 5, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017022026017/0000950170-22-026017-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}